Compass Therapeutics Inc (CMPX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Compass Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Compass Therapeutics Inc's ROI in the second quarter of 2026?
Compass Therapeutics Inc recorded a cumulative net loss of $-73 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -37.03%.
Within the Healthcare sector 404 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2139 to 3604.
BOSTON, Jan. 08, 2025 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on the development of antibody-based therapeutics for various oncology-related diseases, has provided a corporate and financial update revealing formidable challenges intertwined with optimistic progress in their drug development pipeline.In their recent announcement, Compass Therapeutics reported its stock performance, which is currently trading at approximately 6.7% below its 52-week average. The company’s financial health reflects a troublesome trend, as they recorded a cumulative net loss of $48 million for the 12 months ending in the third quarter of 2024. This significant loss has resulted in a negative return on investment (ROI) of -31.99%, positioning Compass Therapeutics unfavorably compared to 363 other companies within the healthcare sector that have reported higher ROI figures.
Compass Therapeutics Strengthens Leadership Team Amid Clinical Progress and Financial ChallengesBOSTON, Dec. 10, 2024 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for oncology, has announced the appointment of Barry Shin as Chief Financial Officer, effective December 9, 2024. Mr. Shin brings over two decades of experience in the biopharmaceutical sector, holding various roles as a finance and operations executive, investment banker, and corporate advisor. His extensive background is seen as a strategic addition to Compass Therapeutics, especially as the company navigates the complexities of clinical development and financial sustainability.Currently, the stock of Compass Therapeutics is trading at a level 1.4% below its 52-week average, reflecting the broader challenges faced by the company. In the latest financial report, the company reported a cumulative net loss of $48 million for the 12 months ending in the third quarter of 2024, which resulted in a negative return on investment of -31.99%. These figures point to the difficult financial landscape that the company must contend with while trying to enhance its research portfolio.
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company specializing in oncology, continues to advance its research portfolio despite facing significant financial hurdles. At the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Houston, Texas, from November 6-10, 2024, the company presented promising new findings related to its lead therapeutic candidate, CTX-471. This novel anti-CD137 agonist antibody is currently being investigated in a Phase 1 clinical trial, targeting immune signaling pathways that can potentially enhance cancer treatment efficacy.During the conference, Compass Therapeutics showcased a poster presentation en
Compass Therapeutics Appoints Dr. Thomas Schuetz as President and CEO, Marking a Significant Transition in Leadership By Boston, May 28, 2024 - Compass Therapeutics, Inc. (Nasdaq: CMPX), a renowned clinical-stage biopharmaceutical company dedicated to developing antibody-based therapeutics for various human diseases, has recently announced a momentous change in its leadership. The company s Board of Directors has appointed Dr. Thomas Schuetz, a highly accomplished and experienced professional, as the new President and Chief Executive Officer (CEO) of Compass Therapeutics, effective from May 28, 2024. Dr. Schuetz, who has been serving as the President of Research and Development and Vice Chair of the Company s Board of Directors, is an eminent personality in the field of oncology and biopharmaceutical research. With a remarkable background that encompasses medical expertise and scientific excellence, his appointment marks a significant strategic move for Compass Therapeutics.
Financial Statements
Compass Therapeutics Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
